TVTX
Travere Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+11/100
Last price
55.50
▼ 2.17 (3.76%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
57.67
Prev close
57.67
Day high
58.77
Day low
55.16
Volume
3.11M
Market cap
$5.28B
P/E (TTM)
—
52W range
22.59 – 68.73
Day trading desk
Gap from prior close
+0.00%
Prior close 57.67
VWAP
56.02
-0.92% from price
Relative volume
2.24×
Unusually busy
Session range
6.76%
55.05 – 58.77
Position in range
12%
Near session low
ATR (14D)
2.45
4.41% of price
Prior day high
58.60
PDH
Prior day low
55.86
PDL
Bid / ask spread
—
Quote not published
Session volume
3.41M
Avg 1.53M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.68%
-8.6%
1M
-14.25%
-15.4%
3M
-4.08%
-8.6%
6M
+76.76%
+58.6%
YTD
+46.51%
+32.3%
1Y
+127.19%
+110.8%
3Y
+526.17%
+443.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TVTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+56.06K
Net buying
Buy transactions
33
414.47K shares
Sell transactions
24
358.41K shares
Net transactions
+57
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
654.17K
Total on file
Fundamentals
Market cap$5.28B
Enterprise value$5.40B
Revenue (TTM)$591.33M
Gross profit$350.12M
EBITDA$22.91M
Net income$-67.68M
EPS (TTM)$-0.74
Free cash flow$-18.25M
Total cash$489.18M
Total debt$616.91M
Book value / share$0.26
Shares outstanding94.26M
Float93.22M
Short % of float17.90%
Dividend yield0.00%
Beta (5Y)1.14
Valuation & profitability ratios
Trailing P/E—
Forward P/E9.87
PEG ratio—
Price / sales—
Price / book215.31
EV / revenue9.14
EV / EBITDA235.87
Gross margin59.21%
Operating margin2.33%
Profit margin-7.35%
Return on equity-236.36%
Return on assets-3.73%
Debt / equity2,515.72
Current ratio4.05
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $490.73M | $233.18M | $145.24M | $109.46M | +110.5% |
| Operating revenue | $490.73M | $233.18M | $145.24M | $109.46M | +110.5% |
| Cost of revenue | $10.34M | $7.74M | $11.45M | $4.42M | +33.5% |
| Gross profit | $480.39M | $225.43M | $133.79M | $105.04M | +113.1% |
| Research & development | $206.01M | $282.70M | $244.99M | $227.33M | -27.1% |
| Selling, general & admin | $337.20M | $264.12M | $265.54M | $197.52M | +27.7% |
| Total operating expense | $543.21M | $546.82M | $510.53M | $424.85M | -0.7% |
| Operating income | -$62.82M | -$321.39M | -$376.74M | -$319.81M | +80.5% |
| Net interest income | $1.97M | $6.63M | $10.43M | -$4.74M | -70.3% |
| Pre-tax income | -$49.27M | -$320.51M | -$376.11M | -$331.15M | +84.6% |
| Tax provision | $988.00K | $120.00K | $223.00K | $313.00K | +723.3% |
| Net income | -$25.55M | -$321.55M | -$111.40M | -$278.48M | +92.1% |
| Net income to common | -$25.55M | -$321.55M | -$111.40M | -$278.48M | +92.1% |
| Basic EPS | -0.29 | -4.08 | -1.50 | -4.37 | +92.9% |
| Diluted EPS | -0.29 | -4.08 | -1.50 | -4.37 | +92.9% |
| EBIT | -$38.52M | -$309.33M | -$364.78M | -$320.14M | +87.5% |
| EBITDA | $22.22M | -$265.77M | -$326.25M | -$299.42M | +108.4% |
| Basic shares | 89.21M | 78.89M | 74.27M | 63.76M | +13.1% |
| Diluted shares | 89.21M | 78.89M | 74.27M | 63.76M | +13.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $93.03M | $58.53M | $58.18M | $61.69M | +58.9% |
| Cash & short-term investments | $322.80M | $370.70M | $566.85M | $450.25M | -12.9% |
| Accounts receivable | $80.13M | $27.12M | $21.18M | $16.65M | +195.5% |
| Inventory | $5.88M | $6.20M | $9.41M | $4.52M | -5.2% |
| Total current assets | $437.56M | $416.70M | $616.77M | $486.44M | +5.0% |
| Property, plant & equipment | $14.60M | $19.63M | $25.54M | $30.05M | -25.6% |
| Goodwill & intangibles | $113.11M | $103.22M | $104.49M | $97.12M | +9.6% |
| Total assets | $605.19M | $594.13M | $788.91M | $672.59M | +1.9% |
| Total current liabilities | $159.90M | $200.75M | $177.91M | $142.16M | -20.3% |
| Current debt | — | $68.68M | — | — | — |
| Long-term debt | $311.72M | $310.31M | $377.26M | $375.55M | +0.5% |
| Total debt | $328.73M | $401.58M | $404.78M | $407.49M | -18.1% |
| Total liabilities | $490.36M | $535.05M | $588.10M | $629.73M | -8.4% |
| Retained earnings | -$1.47B | -$1.45B | -$1.13B | -$1.01B | -1.8% |
| Shareholder equity | $114.83M | $59.08M | $200.81M | $42.85M | +94.4% |
| Working capital | $277.66M | $215.95M | $438.87M | $344.27M | +28.6% |
| Net tangible assets | $1.71M | -$44.14M | $96.32M | -$54.27M | +103.9% |
| Shares issued | 90.92M | 87.45M | 75.37M | 64.29M | +4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$50.26M | -$320.63M | -$376.33M | -$331.47M | +84.3% |
| Depreciation & amortisation | $60.74M | $43.55M | $38.53M | $20.72M | +39.5% |
| Stock-based compensation | $44.87M | $36.91M | $44.25M | $38.14M | +21.6% |
| Change in working capital | -$14.00M | -$63.02M | -$25.48M | $875.00K | +77.8% |
| Operating cash flow | $37.78M | -$237.47M | -$280.02M | -$186.29M | +115.9% |
| Capital expenditure | -$58.16M | -$101.21M | -$41.59M | -$28.37M | +42.5% |
| Investing cash flow | $27.89M | $99.33M | $55.78M | -$32.55M | -71.9% |
| Financing cash flow | -$33.47M | $139.42M | $218.75M | $117.57M | -124.0% |
| Free cash flow | -$20.37M | -$338.69M | -$321.61M | -$214.66M | +94.0% |
| End cash position | $93.03M | $58.53M | $58.18M | $61.69M | +58.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $169.58M | $127.20M | $129.69M | $164.86M | $114.45M | +33.3% |
| Operating revenue | $169.58M | $127.20M | $129.69M | $164.86M | $114.45M | +33.3% |
| Cost of revenue | $9.23M | $26.77M | $2.55M | $1.58M | $15.16M | -65.5% |
| Gross profit | $160.35M | $100.43M | $127.14M | $163.27M | $99.29M | +59.7% |
| Research & development | $60.28M | $57.09M | $57.87M | $51.89M | $49.36M | +5.6% |
| Selling, general & admin | $96.11M | $80.25M | $101.69M | $86.45M | $62.58M | +19.8% |
| Total operating expense | $156.40M | $137.35M | $159.56M | $138.34M | $111.94M | +13.9% |
| Operating income | $3.95M | -$36.91M | -$32.43M | $24.93M | -$12.65M | +110.7% |
| Net interest income | $1.22M | $284.00K | $296.00K | $296.00K | $441.00K | +330.3% |
| Pre-tax income | -$35.00M | -$36.72M | -$21.07M | $25.71M | -$12.73M | +4.7% |
| Tax provision | -$204.00K | -$120.00K | $921.00K | $8.00K | $20.00K | -70.0% |
| Net income | -$34.80M | -$37.10M | $2.73M | $25.71M | -$12.76M | +6.2% |
| Net income to common | -$34.80M | -$37.10M | $2.73M | $25.71M | -$12.76M | +6.2% |
| Basic EPS | -0.37 | -0.40 | 0.03 | 0.29 | -0.14 | +7.5% |
| Diluted EPS | -0.37 | -0.40 | 0.03 | 0.28 | -0.14 | +7.5% |
| EBIT | -$32.87M | -$34.42M | -$18.77M | $28.46M | -$9.89M | +4.5% |
| EBITDA | -$28.63M | -$9.21M | -$632.00K | $44.25M | $4.13M | -210.9% |
| Basic shares | 93.48M | 91.87M | 90.29M | 89.23M | 88.95M | +1.8% |
| Diluted shares | 93.48M | 91.87M | 90.29M | 102.62M | 88.95M | +1.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $117.73M | $78.36M | $93.03M | $110.93M | $75.15M | — | +50.2% |
| Cash & short-term investments | $489.18M | $264.68M | $322.80M | $254.53M | $319.54M | — | +84.8% |
| Accounts receivable | $80.64M | $87.30M | $80.13M | $82.98M | $38.72M | — | -7.6% |
| Inventory | $7.83M | $6.36M | $5.88M | $5.55M | $4.09M | — | +23.3% |
| Total current assets | $615.14M | $392.68M | $437.56M | $371.11M | $379.57M | — | +56.7% |
| Property, plant & equipment | $11.98M | $13.29M | $14.60M | $15.78M | $16.90M | — | -9.9% |
| Goodwill & intangibles | $130.76M | $110.09M | $113.11M | $109.48M | $105.65M | — | +18.8% |
| Total assets | $799.36M | $555.19M | $605.19M | $538.58M | $555.31M | — | +44.0% |
| Total current liabilities | $152.03M | $125.44M | $159.90M | $135.07M | $189.54M | — | +21.2% |
| Current debt | — | — | — | — | $68.84M | $68.76M | — |
| Long-term debt | $602.78M | $312.08M | $311.72M | $311.37M | $311.02M | — | +93.2% |
| Total debt | $616.90M | $327.66M | $328.73M | $329.75M | $399.57M | — | +88.3% |
| Total liabilities | $774.84M | $456.46M | $490.36M | $465.02M | $522.56M | — | +69.7% |
| Retained earnings | -$1.54B | -$1.51B | -$1.47B | -$1.48B | -$1.50B | — | -2.3% |
| Shareholder equity | $24.52M | $98.73M | $114.83M | $73.56M | $32.75M | — | -75.2% |
| Working capital | $463.12M | $267.24M | $277.66M | $236.04M | $190.03M | — | +73.3% |
| Net tangible assets | -$106.24M | -$11.36M | $1.71M | -$35.92M | -$72.91M | — | -835.4% |
| Shares issued | 94.17M | 92.40M | 90.92M | 89.46M | 89.10M | — | +1.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$34.80M | -$36.60M | -$21.99M | $25.71M | -$12.76M | +4.9% |
| Depreciation & amortisation | $4.23M | $25.21M | $18.14M | $15.79M | $14.02M | -83.2% |
| Stock-based compensation | $21.79M | $16.15M | $11.46M | $11.26M | $10.65M | +34.9% |
| Change in working capital | $28.50M | -$45.12M | $52.67M | -$37.33M | -$5.64M | +163.2% |
| Operating cash flow | $58.07M | -$40.37M | $60.68M | $14.32M | $4.98M | +243.9% |
| Capital expenditure | -$21.07M | -$22.18M | -$18.86M | -$15.42M | -$12.09M | +5.0% |
| Investing cash flow | -$206.29M | $21.55M | -$104.84M | $86.59M | $4.85M | -1,057.3% |
| Financing cash flow | $187.52M | $4.20M | $26.68M | -$65.34M | $1.48M | +4,360.4% |
| Free cash flow | $37.00M | -$62.54M | $41.81M | -$1.11M | -$7.10M | +159.2% |
| End cash position | $117.73M | $78.36M | $93.03M | $110.93M | $75.15M | +50.2% |
Options analytics
Put / call volume
0.28
Call-heavy session
Put / call open interest
0.21
Positioning, not flow
Max pain
60.00
+7.2% from spot
ATM implied vol
59.4%
Nearest strike to spot
Skew (10% OTM)
+24.6%
Puts bid over calls
Call volume
47
Contracts, this expiry
Put volume
13
Contracts, this expiry
Heaviest call OI
75.00
471 contracts
Heaviest put OI
67.50
66 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.32 | -0.10 | -131.0% |
| Mar 2026 | -0.06 | 0.05 | +187.0% |
| Dec 2025 | 0.37 | 0.37 | -0.8% |
| Sep 2025 | -0.09 | 0.59 | +794.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.52 | 8 | $195.68M | +18.7% |
| Next quarter | 1.14 | 8 | $232.12M | +79.0% |
| Current year | 1.74 | 8 | $724.56M | +47.7% |
| Next year | 5.67 | 8 | $1.08B | +49.4% |
Analyst targets & ownership
Mean target$75.21
High target$90.00
Low target$62.00
Implied upside35.52%
Analyst count14
ConsensusSTRONG BUY
Strong buy / Buy2 / 12
Hold1
Sell / Strong sell0 / 0
Held by insiders0.69%
Held by institutions115.10%
Institutions holding437
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
58.78
-5.57% from price
SMA 20
61.50
-8.98% from price
SMA 50
62.25
-10.07% from price
SMA 100
57.14
-2.86% from price
SMA 200
45.22
+23.80% from price
EMA 12
59.16
-6.18% from price
EMA 26
60.93
-8.91% from price
EMA 50
60.59
-8.39% from price
RSI (14)
34.1
Neutral
MACD (12,26,9)
-1.78
Hist -0.70
ATR (14)
2.45
4.37% of price
Realised vol 30D
34.3%
Annualised
Bollinger upper
68.19
20, 2σ
Bollinger lower
54.82
20, 2σ
50 / 200 cross
Golden
62.25 vs 45.22
Trend bias
Above 200
+23.80%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.38
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
34.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-33.5%
Peak to trough
Max drawdown 5Y
-83.1%
Peak to trough
ATR 14
2.45
4.37% of price
Beta (reported)
1.14
5Y monthly, from filing
Short interest
Shares short
12.96M
Prior 11.94M
Change vs prior
+8.5%
Shorts adding
% of float
17.90%
Elevated
% of shares out
13.74%
Against total outstanding
Days to cover
10.2
Crowded exit
Float
93.22M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 22, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 22, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 10, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Aug 6, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 5, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Aug 5, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Aug 5, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 30, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jun 25, 26 | Guggenheim | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-21
Periodic Financial Reports
10-Q · 2026-08-04
Corporate Changes & Voting Matters
8-K · 2026-07-09
Offering Registrations
S-8 · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-06-16
Corporate Changes & Voting Matters
8-K · 2026-06-02
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-05-11
Headlines
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
Business Wire · 5d ago
Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI
MT Newswires · 14d ago
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Business Wire · 14d ago
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026
Simply Wall St. · 14d ago
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today
Simply Wall St. · 15d ago
Travere Therapeutics President and CEO Eric Dube Plans to Step Down
MT Newswires · 15d ago
Travere Therapeutics Announces Planned Chief Executive Officer Transition
Business Wire · 15d ago
Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing
MT Newswires · 19d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.